Rapidly spreading diseases and unpredictable global shifts cause increased strain to the pharmaceutical supply chain, jeopardizing the secure delivery of drugs to those who are in need. Artificial intelligence can maximize efficacy of the value chain and allow optimal responses to changing market demands. Two experts share insights into the possibilities and hurdles associated with integration of machine learning tools into the pharmaceutical supply chain.
OHMX.bio provides innovative omics solutions using state-of-the-art sequencing and mass spectrometry platforms. Specializing in expression analysis (RNA-seq and RIBO-seq) and epigenetic profiling, as well as companion diagnostics, the company uses second- and third-generation sequencing technology to enable scientific insights and build assays for better drug and therapy development. With both a wet lab and dry lab in house, OHMX.bio offers a full-circle service to biotech and pharma partners.
Byteflies is on a mission to make virtual care available to all. The Belgian company has developed a platform for remote patient monitoring solutions, to save precious time for healthcare providers, reduce hospitalization costs, and boost the quality of life for patients. The aim is to aid the transition from fragmented to connected healthcare, enabling a continuum of care through virtual solutions.
Silicon Valley investment gurus have long promoted the idea that startups should ‘fake it till you make it’ to become successful. The infamous fall of Theranos is a perfect showcase of how this attitude can turn into a disaster. We take a closer look at this philosophy of exaggeration and weigh up the merits of ‘fact vs. fiction’ when life sciences entrepreneurs are dealing with potential investors.
Patient data can be extremely helpful for improving health. If properly utilized, valuable insights can be generated, leading to better care for all. To do this, we need a way to overcome the incompatibility of information systems used by different healthcare providers, so that we are able to conduct large-scale research projects using data from multiple sources. The key to this lies in implementing data standards, such as OMOP and FHIR – specific methods developed for the storage, sharing, and interpretation of healthcare data.
Corteria Pharmaceuticals is developing transformative therapies for heart failure subpopulations most likely to benefit from the company’s novel cardiorenal treatments. The company was founded in 2021 by Sanofi’s former head of cardiovascular research, Philip Janiak, and Marie-Laure Ozoux, former cardiovascular project leader at Sanofi.
CoMoveIT is a striking example of how visionary ideas can be turned into life-changing innovations once the right technology becomes available. We spoke with CoMoveIT’s CTO, Sotirios Gakopoulos, about the Belgian company’s unique solution to improve the mobility of patients with complex movement disorders, like cerebral palsy.
Many drugs fail clinical trials, often because preclinical animal models fall short of replicating human physiology. To improve animal welfare, speed up drug development, and reduce costs, we need to rely less on animal models, while also minimizing the number of failures early in the drug development process. Artificial intelligence and machine learning are powerful tools that can help us achieve these goals by predicting a drug's efficacy, safety, and uptake in preclinical studies. These technologies can help researchers to make informed decisions and optimize testing strategies, improving drug development for both animals and people.
Rapidly spreading diseases and unpredictable global shifts cause increased strain to the pharmaceutical supply chain, jeopardizing the secure delivery of drugs to those who are in need. Artificial intelligence can maximize efficacy of the value chain and allow optimal responses to changing market demands. Two experts share insights into the possibilities and hurdles associated with integration of machine learning tools into the pharmaceutical supply chain.
OHMX.bio provides innovative omics solutions using state-of-the-art sequencing and mass spectrometry platforms. Specializing in expression analysis (RNA-seq and RIBO-seq) and epigenetic profiling, as well as companion diagnostics, the company uses second- and third-generation sequencing technology to enable scientific insights and build assays for better drug and therapy development. With both a wet lab and dry lab in house, OHMX.bio offers a full-circle service to biotech and pharma partners.
Byteflies is on a mission to make virtual care available to all. The Belgian company has developed a platform for remote patient monitoring solutions, to save precious time for healthcare providers, reduce hospitalization costs, and boost the quality of life for patients. The aim is to aid the transition from fragmented to connected healthcare, enabling a continuum of care through virtual solutions.
Silicon Valley investment gurus have long promoted the idea that startups should ‘fake it till you make it’ to become successful. The infamous fall of Theranos is a perfect showcase of how this attitude can turn into a disaster. We take a closer look at this philosophy of exaggeration and weigh up the merits of ‘fact vs. fiction’ when life sciences entrepreneurs are dealing with potential investors.
Patient data can be extremely helpful for improving health. If properly utilized, valuable insights can be generated, leading to better care for all. To do this, we need a way to overcome the incompatibility of information systems used by different healthcare providers, so that we are able to conduct large-scale research projects using data from multiple sources. The key to this lies in implementing data standards, such as OMOP and FHIR – specific methods developed for the storage, sharing, and interpretation of healthcare data.
Corteria Pharmaceuticals is developing transformative therapies for heart failure subpopulations most likely to benefit from the company’s novel cardiorenal treatments. The company was founded in 2021 by Sanofi’s former head of cardiovascular research, Philip Janiak, and Marie-Laure Ozoux, former cardiovascular project leader at Sanofi.
CoMoveIT is a striking example of how visionary ideas can be turned into life-changing innovations once the right technology becomes available. We spoke with CoMoveIT’s CTO, Sotirios Gakopoulos, about the Belgian company’s unique solution to improve the mobility of patients with complex movement disorders, like cerebral palsy.
Many drugs fail clinical trials, often because preclinical animal models fall short of replicating human physiology. To improve animal welfare, speed up drug development, and reduce costs, we need to rely less on animal models, while also minimizing the number of failures early in the drug development process. Artificial intelligence and machine learning are powerful tools that can help us achieve these goals by predicting a drug's efficacy, safety, and uptake in preclinical studies. These technologies can help researchers to make informed decisions and optimize testing strategies, improving drug development for both animals and people.